<DOC>
	<DOCNO>NCT00343980</DOCNO>
	<brief_summary>This trial conduct Asia , Europe Oceania . The aim research study compare efficacy add inhaled preprandial insulin glimepiride compare add rosiglitazone glimepiride treatment type 2 diabetes verify safety ( hypoglycaemia , pulmonary function , body weight , insulin antibody side effect )</brief_summary>
	<brief_title>Safety Efficacy Inhaled Pre-prandial Human Insulin Type 2 Diabetes</brief_title>
	<detailed_description>The decision discontinue development AERxÂ® due safety concern . An analysis conclude fast-acting inhaled insulin form know today , unlikely offer significant clinical convenience benefit injection modern insulin pen device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 diabetes Treated OAD ( ) equal 2 month Body mass index ( BMI ) less equal 40.0 kg/m2 HbA1c great equal 8.0 % less equal 11.0 % subject OAD monotherapy HbA1c great equal 7.5 % less equal 10.0 % subject OAD combination therapy Recurrent major hypoglycaemia Current smoking smoking within last 6 month Impaired hepatic renal function Cardiac problem Uncontrolled hypertension Proliferative retinopathy maculopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>